IL18 and hyperinsulinemic hypoglycemia, familial, 4: Six IL-6 blockers for SLE treatments and one IL-18 inhibitor for patients with NLRC4 and XIAP deficiency (monogenic IL-18 associated autoinflammatory conditions) are in phase II/III clinical trials (Table 1) [6, 198, 201–205].